BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30663564)

  • 1. Serum α-1 Acid Glycoprotein is a Biomarker for the Prediction of Targeted Therapy Resistance in Advanced EGFR-positive Lung Adenocarcinoma.
    Xu YF; Xu Y; Li X; Yang XM
    Comb Chem High Throughput Screen; 2018; 21(10):755-759. PubMed ID: 30663564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
    Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
    J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAK1 Is a Novel Therapeutic Target in Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma Activated by the PI3K/AKT Signaling Regardless of EGFR Mutation.
    Wu DW; Wu TC; Chen CY; Lee H
    Clin Cancer Res; 2016 Nov; 22(21):5370-5382. PubMed ID: 27178741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas.
    Lee TF; Tseng YC; Nguyen PA; Li YC; Ho CC; Wu CW
    Sci Rep; 2018 Jan; 8(1):271. PubMed ID: 29321482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FGA isoform as an indicator of targeted therapy for EGFR mutated lung adenocarcinoma.
    Shang Z; Niu X; Zhang K; Qiao Z; Liu S; Jiang X; Cao C; Lu S; Xiao H
    J Mol Med (Berl); 2019 Dec; 97(12):1657-1668. PubMed ID: 31776635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
    Li H; Wang Y; Su F; Li J; Gong P
    Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin improves sensitivity to tyrosine kinase inhibitor in lung adenocarcinoma in vitro by promoting epidermal growth factor receptor phosphorylation.
    Wang YJ; Wang QW; Yu DH; Song CK; Guo ZX; Liu XP; Chen C; Yao J; Wang AF; Hu WD
    J Cancer Res Clin Oncol; 2021 Nov; 147(11):3245-3254. PubMed ID: 34255150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
    Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
    Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of tumor immune microenvironment via microRNA-1 after epidermal growth factor receptor-tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma.
    Kawana S; Saito R; Miki Y; Kimura Y; Abe J; Sato I; Endo M; Sugawara S; Sasano H
    Cancer Med; 2021 Jan; 10(2):718-727. PubMed ID: 33305905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Level of soluble programmed death-1 ligand 1 in peripheral blood of patients with advanced epidermal growth factor receptor mutated lung adenocarcinoma and its clinical implications].
    Zhang LQ; Chen Y; Pan X; Xing YF; Shi MH; Chen YJ
    Zhonghua Yi Xue Za Zhi; 2016 Dec; 96(48):3870-3874. PubMed ID: 28057155
    [No Abstract]   [Full Text] [Related]  

  • 12. A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma.
    Han X; Liang L; He C; Ren Q; Su J; Cao L; Zheng J
    BMC Complement Med Ther; 2023 Nov; 23(1):422. PubMed ID: 37990309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
    Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
    Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-talk between SOX2 and TGFβ Signaling Regulates EGFR-TKI Tolerance and Lung Cancer Dissemination.
    Kuo MH; Lee AC; Hsiao SH; Lin SE; Chiu YF; Yang LH; Yu CC; Chiou SH; Huang HN; Ko JC; Chou YT
    Cancer Res; 2020 Oct; 80(20):4426-4438. PubMed ID: 32816907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Significance of MMP-1 in EGFR-TKI-Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting.
    Saito R; Miki Y; Ishida N; Inoue C; Kobayashi M; Hata S; Yamada-Okabe H; Okada Y; Sasano H
    Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29463039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct activation of PP2A for the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma.
    Tohmé R; Izadmehr S; Gandhe S; Tabaro G; Vallabhaneni S; Thomas A; Vasireddi N; Dhawan NS; Ma'ayan A; Sharma N; Galsky MD; Ohlmeyer M; Sangodkar J; Narla G
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma.
    Hong X; Hsieh MT; Tseng TY; Lin HY; Chang HC; Yau ST; Cheng WC; Ke B; Liao HH; Wu CY; Liu AA; Wu MM; Huang KY; Yang PC; Kuo SC; Hung MC; Lee PC
    J Biol Chem; 2023 Jun; 299(6):104814. PubMed ID: 37178919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early serum tumor marker levels after fourteen days of tyrosine kinase inhibitor targeted therapy predicts outcomes in patients with advanced lung adenocarcinoma.
    Chen HJ; Tu CY; Huang KY; Chien CR; Hsia TC
    PLoS One; 2020; 15(12):e0240736. PubMed ID: 33306683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.